AIMMED’s Digital Therapeutics, Somzz helps relieve insomnia with Cognitive-Behavioural Therapy
AIMMED Corp. is a leading digital therapeutics company based in Seoul, South Korea. AIMMED creates digital healthcare systems as a frontrunner in South Korea’s DTx (Digital Therapeutics) industry as well as the field of the healthcare platforms and senior care.
Since 2019, AIMMED has consistently expanded its product pipeline across a broad-spectrum of disease areas. It continues to discover, develop, and improve software-based therapeutics with the aim of creating more effective and personalized products for patients and convenient products for clinicians to manage treatment.
AIMMED uses evidence-based medicine (EBM) to ensure the safety and clinical effectiveness of its products to achieve better outcomes for patients worldwide.
Product profile
Somzz is a digital therapeutics mobile app designed for adults suffering from insomnia. Somzz applies and implements the protocols of Cognitive-Behavioural Therapy for Insomnia (Stimulus Control Therapy, Sleep Restriction Therapy, Sleep Hygiene Education, Relaxation Techniques, and Cognitive Therapy) through a mobile app.
In clinical practice, this is considered the first-line treatment recommended for insomnia. Somzz provides education, real-time feedback, behaviour intervention, and algorithm-based push notifications to patients with insomnia over 6 to 9 weeks.
Indications for use
Somzz is a Software as a Medical Device (SaMD) intended to improve insomnia symtoms by delivering a medical intervention (Cognitive-Behavioural Therapy for Insomnia, CBT-I) in the form of a mobile app.
Prescription status
A prescription from a qualified healthcare provider is required.
Unique features
- Expanded treatment options: Introducing a new treatment in addition to traditional medications and face-to-face CBT-I
- Remote access: Available via online access without physical constraints of space and time
- Real-time feedback: Making it easy to track progress and engage patients actively in their treatment
- Safety: Non-invasive and non-pharmacological, which makes it less prone to safety issues.
Clinical outcomes
In a clinical trial, the efficacy of Somzz for patients with chronic insomnia was proven superior to a placebo device, which consisted of a sleep diary and sleep hygiene education. It demonstrated statistically significant improvement in insomnia severity scores at the end of treatment. The efficacy of Somzz was also observed in the assessment scales, which measure dysfunctional beliefs about sleep, depressive symptoms, fatigue, daytime sleepiness, health related quality of life, as well as sleep quality which includes sleep efficiency and sleep onset latency.
In particular, 46.81% of the patients reached remission at the end of the treatment program.
